Treatment News : HIV Vaccine Study Offers Up Possible Antibody Protection Clues - by Reed Vreeland

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » April 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

April 9, 2012

HIV Vaccine Study Offers Up Possible Antibody Protection Clues

by Reed Vreeland

Scientists continued to unravel clues as to why a combination of two preventive HIV vaccines—ALVAC HIV and AIDSVAX B/E—may have worked for some but not others in a large scale clinical trial reported in 2009. A new paper published online ahead of print in The New England Journal of Medicine (NEJM) suggests those who produced relatively high levels of a specific antibody after receiving the vaccinations in study RV 144 were less likely to become infected with HIV, compared with those who did not.

“This analysis has produced some intriguing hints about what types of human immune responses a preventive HIV vaccine may need to induce,” said National Institute of Allergy and Infectious Diseases director Anthony S. Fauci, MD, in a news announcement highlighting the post-study data analysis. “With further exploration, this new knowledge may bring us a step closer to developing a broadly protective HIV vaccine.”

In the RV 144 clinical trial, which involved more than 16,000 adult volunteers in Thailand, the group that received ALVAC HIV and AIDSVAX B/E had a 31 percent lower chance of becoming infected with HIV than the group that received a placebo. Initially, the difference between the two groups was considered to be statistically significant—modest, but great enough to have not occurred by chance. A second statistical analysis, however, failed to confirm a statistically significant difference between the two groups.

Still, a consortium of scientists has remained dedicated to searching for molecular clues to explain why the vaccines at least showed a trend toward benefit.

The new report describes an analysis of blood samples taken from a subset of study participants, notably 41 who were vaccinated and later became infected with HIV and 205 vaccinated participants who remained uninfected.

The participants who made relatively high levels of one antibody to HIV were significantly less likely to become infected than those who did not. This particular binding antibody attaches to a part of the outer coat of the virus called the first and second variable regions, or V1V2, which may play an important role in HIV infection of human cells. The antibody belongs to a family called immunoglobulin G, or IgG.

Conversely, high levels of a different type of HIV binding antibody—an immunoglobulin A, or IgA, antibody that attaches to another part of the virus’s coat, known as the first constant region, or C1—was associated with less protection against infection with the virus. According to the scientists, under the direction of Barton Haynes, MD, of Duke Human Vaccine Institute in Durham, North Carolina, the C1 IgA antibody either was associated with less benefit from HIV vaccination or directly reduced the benefit of vaccination.

Next up, scientists will conduct primate studies to determine whether high levels of V1V2 antibodies directly caused the modest protective effect seen in the RV 144 study or simply were linked to other, still unidentified factors responsible for the trial’s encouraging outcome. Such testing also will determine whether the V1V2 antibody response is merely a marker of HIV exposure or decreased susceptibility to HIV infection.

The study authors note that different vaccine candidates may protect against HIV in different ways. Therefore, more research is needed to understand whether these new findings will be relevant to other types of HIV vaccines or to similar vaccines tested against HIV strains from other regions or against different routes of exposure to the virus.

Search: rv 144, alvac, aidsvax, vaccine, prevention, preventive, iga, igg, ALVAC v1v2, c1, antibody


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    usuallyhappy
    Palm Springs
    California


    cortaza100
    Oakland
    California


    blaze11212
    brooklyn
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.